+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transcriptomic Microarray Analysis of the Early Response to Treatment of Hepatitis C Virus (Hcv) with Pegylated Interferon and Ribavirin



Transcriptomic Microarray Analysis of the Early Response to Treatment of Hepatitis C Virus (Hcv) with Pegylated Interferon and Ribavirin



Gastroenterology 134(4): A-753




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067059491

Download citation: RISBibTeXText

DOI: 10.1016/s0016-5085(08)63518-0


Related references

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

S1005 Very Early Viral Response to Treatment of Hepatitis C Virus (Hcv) with Pegylated Interferon and Ribavirin: the First 24 Hours. Gastroenterology 134(4): A-773, 2008

Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. European Journal of Gastroenterology and Hepatology 23(2): 177-183, 2011

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49(6): 1847-1858, 2009

W1015 Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection. Gastroenterology 134(4): A-832, 2008

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Journal of Gastroenterology and Hepatology 23(6): 861-866, 2008

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 54(6): 2278-2279, 2011

Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Virology Journal 8: 234, 2011

Effects of Host and virus related factors on Interferon-alpha+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients. 2011

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Preliminary treatment results of pegylated interferon alpha 2b and ribavirin in liver transplant recipients with recurrent hepatitis C virus nonresponsive to interferon alpha2b and ribavirin. Journal of Hepatology 38(Suppl. 2): 160, 2003

Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin. Intervirology 58(1): 27-34, 2015

Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. European Journal of Clinical Microbiology and Infectious Diseases 34(10): 1929-1936, 2015

Preliminary treatment results of liver transplant recipients with recurrent Hepatitis C Virus nonresponsive to interferon alpha2b and ribavirin using combination pegylated interferon alpha 2b with ribavirin. Hepatology 36(4 Part 2): 183A, 2002

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 53(3): 146-153, 2010